Kura Oncology, Inc.
KURA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 35.7% | 8.4% | -73.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.5% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -356.4% | -428.5% | -458.6% | -30.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -357.2% | -432.5% | -407.1% | -35.7% |
| EPS Diluted | -0.85 | -0.75 | -0.66 | -0.22 |
| % Growth | -13.3% | -13.6% | -200% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |